Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Sells off Remaining Stake in RXi

Premium

One-time RNAi drug developer CytRx said this week that it has sold off its remaining equity interest in RXi Pharmaceuticals for roughly $7 million.

RXi was spun out of CytRx in early 2007 to carry forward its RNAi therapeutics programs (GSN 1/11/2007). In 2008, RXi went public (GSN 3/13/2008).

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.